Biotech Values

[DewDiligence]

>MNTA – Do they know what requirement the FDA wants?<

Not yet.

>Sounds that this will include clinical trials and 2 years setback.<

I won’t say this is impossible, but there has never been an ANDA in the history of the FDA that required clinical studies.

In any event, the current share price ascribes no value whatsoever to the Lovenox and Copaxone program. I’m happy buying at these levels based on only M118 and the two undisclosed programs with Sandoz’s compounds.